MEDI 8897

Drug Profile

MEDI 8897

Alternative Names: Anti-RSV mAb D25; Anti-RSV MAb-YTE; MEDI-8897; Respiratory syncytial virus monoclonal antibody D25

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator AIMM Therapeutics
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Respiratory syncytial virus infections (In infants, Prevention) in Spain, South Africa, Italy, Hungary, Czech Republic, Bulgaria, United Kingdom, USA (Parenteral) (NCT02878330)
  • 01 Sep 2016 MedImmune completes a phase Ib/IIa trial for Respiratory syncytial virus infections (In healthy preterm infants) in USA, Chile and South Africa (NCT02290340)
  • 25 Aug 2016 MedImmune plans a phase IIb trial for Respiratory syncytial virus infections (In infants, Prevention) in USA, United Kingdom, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czech Republic, Finland, France, Germany, Hungary, Italy, New Zealand, Poland, Russia, South Africa, Spain and Sweden (unspecified route) (NCT02878330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top